TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.
Image Source: Pixabay
SenesTech Inc. (SNES), a biotechnology firm specializing in non-toxic rodent control solutions, is quietly making major strides in municipal adoption, international expansion, and retail penetration. Following an exclusive CEO interview on YouTube and a panel discussion on X Spaces, recent press releases indicate that the company is on the verge of significant growth in 2025.
Video Length: 00:28:34
With a market capitalization of only $3 million and just 1 million shares outstanding (2 million fully diluted), SNES remains largely undiscovered by investors—despite having a first-mover advantage in rodent fertility control and securing major partnerships.
This blog post has been upgraded to a full free article here.
Comments
Log in or sign up to join the conversation.